WHO ICTRP trial
intralesional rituximab in pemphigus vulgaris
IRCT20181224042105N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20181224042105N1 |
|---|---|
| Public title | intralesional rituximab in pemphigus vulgaris |
| Scientific title | comparison between the efficacy of intralesional rituximab and intralesional triamcinolone in the treatment of patients with refractory pemphigus vulgaris |
| Primary sponsor | Esfahan University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | pemphigus vulgaris. Pemphigus vulgaris |
| Interventions | Intervention 1: Intervention group 1: 1cc intralesional ritumab10 mg/ml will be injected in 21 lesions and after one month will be repeated. Intervention 2: Intervention group 1: 1cc intralesional triamcinolone10 mg/ml will be injected in… |
| Registration date | Jan 1, 2019 |
| Target size | 20 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: